[{"address1": "230 Park Avenue", "address2": "Suite 3350", "city": "New York", "state": "NY", "zip": "10169", "country": "United States", "phone": "646 885 8505", "website": "https://www.ymabs.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of radioimmunotherapy and antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, an antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma. In addition, it engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center, and MSK and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.", "fullTimeEmployees": 104, "companyOfficers": [{"maxAge": 1, "name": "Mr. Michael  Rossi", "age": 53, "title": "CEO, President & Director", "yearBorn": 1971, "fiscalYear": 2023, "totalPay": 481205, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Thomas  Gad", "age": 54, "title": "Founder, Chief Business Officer & Vice Chairman", "yearBorn": 1970, "fiscalYear": 2023, "totalPay": 1111627, "exercisedValue": 0, "unexercisedValue": 901500}, {"maxAge": 1, "name": "Mr. Peter P. Pfreundschuh CPA", "age": 55, "title": "CFO & Treasurer", "yearBorn": 1969, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Joris Wiel Jan Wilms", "age": 50, "title": "Senior VP & COO", "yearBorn": 1974, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Torben  Lund-Hansen M.Sc., Ph.D.", "age": 73, "title": "Senior VP & CTO", "yearBorn": 1951, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Courtney  Dugan", "title": "Vice President of Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Vignesh  Rajah M.B.A., MBBS", "age": 59, "title": "Senior VP & Chief Medical Officer", "yearBorn": 1965, "fiscalYear": 2023, "totalPay": 406275, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Norman D.  LaFrance FACNP, FACP, M.D.", "age": 76, "title": "Chief Development Officer", "yearBorn": 1948, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Doug  Gentilcore", "title": "Senior VP & Head of DANYELZA Business Unit", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 8, "boardRisk": 6, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1740787200, "compensationAsOfEpochDate": 1703980800, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 4.73, "open": 4.77, "dayLow": 4.64, "dayHigh": 4.86, "regularMarketPreviousClose": 4.73, "regularMarketOpen": 4.77, "regularMarketDayLow": 4.64, "regularMarketDayHigh": 4.86, "payoutRatio": 0.0, "beta": 0.647, "forwardPE": -8.051724, "volume": 206717, "regularMarketVolume": 206717, "averageVolume": 452645, "averageVolume10days": 377890, "averageDailyVolume10Day": 377890, "bid": 0.0, "ask": 0.0, "bidSize": 0, "askSize": 0, "marketCap": 211168992, "fiftyTwoWeekLow": 4.25, "fiftyTwoWeekHigh": 17.78, "priceToSalesTrailing12Months": 2.4082682, "fiftyDayAverage": 6.0552, "twoHundredDayAverage": 10.8177, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 144754880, "profitMargins": -0.33832002, "floatShares": 27714221, "sharesOutstanding": 45218200, "sharesShort": 4725453, "sharesShortPriorMonth": 4025266, "sharesShortPreviousMonthDate": 1738281600, "dateShortInterest": 1740700800, "sharesPercentSharesOut": 0.104499996, "heldPercentInsiders": 0.12316, "heldPercentInstitutions": 0.72202003, "shortRatio": 9.49, "shortPercentOfFloat": 0.1251, "impliedSharesOutstanding": 48915300, "bookValue": 2.045, "priceToBook": 2.2836185, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1735603200, "netIncomeToCommon": -29666000, "trailingEps": -0.67, "forwardEps": -0.58, "enterpriseToRevenue": 1.651, "enterpriseToEbitda": -5.89, "52WeekChange": -0.66061044, "SandP52WeekChange": 0.09506309, "quoteType": "EQUITY", "currentPrice": 4.67, "targetHighPrice": 26.0, "targetLowPrice": 7.0, "targetMeanPrice": 18.0, "targetMedianPrice": 18.5, "recommendationMean": 1.7, "recommendationKey": "buy", "numberOfAnalystOpinions": 10, "totalCash": 67234000, "totalCashPerShare": 1.487, "ebitda": -24575000, "totalDebt": 820000, "quickRatio": 3.668, "currentRatio": 4.157, "totalRevenue": 87685000, "debtToEquity": 0.891, "revenuePerShare": 1.978, "returnOnAssets": -0.12668, "returnOnEquity": -0.30743998, "grossProfits": 72434000, "freeCashflow": 4441250, "operatingCashflow": -15714000, "revenueGrowth": 0.134, "grossMargins": 0.82607, "ebitdaMargins": -0.28026, "operatingMargins": -0.16466999, "financialCurrency": "USD", "symbol": "YMAB", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "shortName": "Y-mAbs Therapeutics, Inc.", "longName": "Y-mAbs Therapeutics, Inc.", "messageBoardId": "finmb_378585331", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "corporateActions": [], "postMarketTime": 1741983811, "regularMarketTime": 1741982400, "exchange": "NMS", "marketState": "CLOSED", "cryptoTradeable": false, "regularMarketChangePercent": -1.2684977, "regularMarketPrice": 4.67, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1537536600000, "postMarketChangePercent": 0.0, "postMarketPrice": 4.67, "postMarketChange": 0.0, "regularMarketChange": -0.059999943, "regularMarketDayRange": "4.64 - 4.86", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 452645, "fiftyTwoWeekLowChange": 0.42000008, "fiftyTwoWeekLowChangePercent": 0.09882355, "fiftyTwoWeekRange": "4.25 - 17.78", "fiftyTwoWeekHighChange": -13.110001, "fiftyTwoWeekHighChangePercent": -0.73734534, "fiftyTwoWeekChangePercent": -66.06104, "earningsTimestamp": 1741088100, "earningsTimestampStart": 1746442740, "earningsTimestampEnd": 1746792000, "earningsCallTimestampStart": 1741093200, "earningsCallTimestampEnd": 1741093200, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -0.67, "epsForward": -0.58, "epsCurrentYear": -0.8875, "priceEpsCurrentYear": -5.261972, "fiftyDayAverageChange": -1.3852, "fiftyDayAverageChangePercent": -0.22876206, "twoHundredDayAverageChange": -6.1477003, "twoHundredDayAverageChangePercent": -0.5683001, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.7 - Buy", "displayName": "Y-mAbs Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-03-15"}]